Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.